Scientists describe antibodies that protect against large variety of flu viruses
- Details
- Category: Research
A team led by scientists at The Scripps Research Institute and Crucell Vaccine Institute in the Netherlands describes three human antibodies that provide broad protection against Influenza B virus strains. The same team had previously reported finding broadly neutralizing antibodies against Influenza A strains.
Grapefruit juice lets patients take lower dose of cancer drug
- Details
- Category: Research
A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself, according to a new clinical trial. The combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication.
Lower risk of serious side-effects in trials of new targeted drugs
- Details
- Category: Research
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust analysed data from 36 Phase I trials run by the organisations' joint Drug Development Unit.
Rejected Alzheimer's drug shows new potential
- Details
- Category: Research
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.
Trial signals major milestone in hunt for new TB drugs
- Details
- Category: Research
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published in the Lancet.
Bloodstream scavenger inhibits clotting without increased bleeding
- Details
- Category: Research
A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots without triggering equally threatening bleeding.
Physicians don't adequately monitor patients' medication adherence
- Details
- Category: Research
Patients' non-adherence to prescribed medication costs the U.S. health care system an estimated $290 billion annually and can lead to poor clinical outcomes, increased hospitalizations and higher mortality.
More Pharma News ...
- Drug fails to curb heart bypass complications, but surgery gets safer
- Study finds drug warning labels need overhaul
- Patient-derived stem cells could improve drug research for Parkinson's
- A better way to test new treatments?
- Researchers block pathway to cancer cell replication
- Patients should be informed about effects of placebos
- New compound holds promise for treating Duchenne MD